Identifying & reducing barriers to oncology clinical research at site level
ICON’s clinical and operational expertise are founded on successful principles, with on-demand access to critical and supportive resources tailored to a early phase oncology trials.
As Immuno-oncology continues to play a more relevant role in cancer treatment, overcoming challenges related to the development of immunotherapies becomes increasingly important.
Recent developments in cancer immunotherapy illustrate virtually unprecedented clinical benefit in some advanced cancer patients, and the potential for cure seems tangible. In line with transforming patient care, we have also already begun to transform drug development.
ICON conducts clinical studies in both solid and haematological tumours including breast, lung, gastric, HCC, prostate, multiple myeloma, AML, lymphoma and leukaemia.
Medical imaging enables improved decision making, increased efficiency, and can reduce trial costs.
ICON's proven paradigm bridges the gap between patients and clinical research sites.
Resources and expertise to identify, generate, synthesize and communicate evidence of treatment value and safety
FIRECREST digital solutions increase efficiency in clinical trials by driving site performance.
ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.
Our consultants can advise you on developing market access and pricing strategies.
The explosion of information about the genetic aberrations underlying cancer has led to several changes in the paradigm of how we develop drugs for this disease. We believe that transformation of the outcomes for patients with cancer will require detailed understanding of these genetic aberrations in each patient’s cancer at diagnosis.
Targeted therapies, novel immunotherapies and the ability to combine these agents together successfully will be important in the development of effective and tolerable treatment regimens.
Understanding the complexities of Conducting Oncology Clinical Trials.Share your feedback